Diabetic macular edema represents a silent threat to working professionals across America. The condition, which causes fluid accumulation in the macula, the eye’s central focusing region, ranks as the leading vision-robbing disease among people in their productive years. Yet despite the availability of anti-angiogenic medications, according to PharmaBiz.com, a substantial proportion of patients experience inadequate symptom control, leaving practitioners and patients searching for alternative approaches.
The Dosing Burden Creates Opportunity
Current treatment paradigms demand frequent interventions. Patients receiving anti-VEGF injections often require monthly or bimonthly appointments to maintain therapeutic effect. For individuals juggling work and family obligations, this treatment frequency becomes burdensome, missed appointments, inconsistent therapy, and suboptimal adherence frequently undermine clinical outcomes.
Eclipse Life Sciences recognized this treatment gap and began developing EC-104, a corticosteroid implant engineered to deliver medication for a full six months following a single intravitreal injection. The company has now advanced this technology into phase 2 evaluation, enrolling its first patient in the BETTIS-1 trial, a randomized, controlled comparison between EC-104 and the established corticosteroid reference product Ozurdex.
Understanding the Clinical Strategy
The BETTIS-1 trial specifically targets a frustrating patient subset: individuals who showed inadequate response to anti-VEGF monotherapy and who tolerated previous corticosteroid treatments without experiencing elevated intraocular pressure complications. Researchers are evaluating two EC-104 dosing strengths (0.14 mg and 0.092 mg) to establish the optimal balance between therapeutic benefit and safety.
The trial’s primary focus addresses safety considerations, a logical priority when advancing novel implant technologies. Secondary assessments measure treatment durability through anatomic imaging (SD-OCT scanning), tracking whether the drug maintains anti-inflammatory effects throughout the projected six-month window.
Meeting an Overlooked Need
The clinical mathematics reveal why this approach matters. Approximately 65% of DME patients demonstrate suboptimal response to anti-VEGF treatment alone, yet many practitioners lack convenient options for these resistant cases. A durable corticosteroid implant offering twice-yearly dosing would transform treatment patterns—converting twelve-times-yearly visits into just two annual appointments while maintaining consistent therapeutic pressure.
Ivan Suñer, MD, principal investigator at Retina Associates of Florida, emphasized this advantage: “EC-104 has the potential to offer improved vision through convenient twice-a-year dosing, particularly for DME patients who haven’t responded adequately to anti-VEGF medications.”
A Broader Pipeline Emerging
EC-104 represents just one element of Eclipse Life Sciences’ ophthalmology portfolio. The company is simultaneously developing EC-303 for intermediate dry AMD and EC-501, a six-month anti-VEGF implant targeting multiple retinal vascular conditions. This multipronged approach suggests Eclipse’s leadership recognizes that extended-release intraocular delivery represents a transformative technology platform applicable across multiple prevalent retinal disorders.
As BETTIS-1 enrollment continues across multiple U.S. clinical sites, the trial outcomes will likely influence how practitioners approach anti-VEGF-resistant DME. If EC-104 demonstrates safety and maintains its intended six-month durability, it could fundamentally reshape treatment convenience and patient adherence in retinal disease management.
